Senti Biosciences Holdings, Inc.
SNTINasdaq
$0.44
↓ -4.9%Jul 17 close · end-of-day
Price
1Y↓ -58.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$13.5M
Enterprise Value
$4.6M
P/E
—
P/S
—
P/B
5.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$51.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-2009.6%
ROIC
—
Debt / Equity
—
Net Cash
$8.9M
Return 1Y
—
Company profile
Dynamics Special Purpose Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination. The company was incorporated in 2021 and is based in Redwood City, California.
- CEO
- Timothy K. Lu
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- California
- Website
- sentibio.com
Management & directors
- Lu Timothy KCEO
- Rajangam KanyaPres. & Chief Med. & Dev. Off.
Roles derived from SEC Form 4 filings.
Earnings
SNTI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$16,000.00—
Diluted EPS-$0.14↓ -90.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $4.3M | $2.6M | $0.00 | $22,000.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.4M | -$62.1M | -$92.7M | -$61.0M | -$68.8M |
| Net income | -$55.3M | -$58.2M | -$71.1M | -$52.8M | -$61.4M |
| Diluted EPS | -$19.00 | -$2.23 | -$16.01 | -$12.03 | -$2.73 |
| Operating cash flow | -$34.6M | -$34.9M | -$52.4M | -$41.4M | -$43.4M |
| Free cash flow | -$40.2M | -$76.3M | -$64.4M | -$41.4M | -$43.6M |
| Gross margin | — | — | — | — | — |
| Operating margin | -1464.9% | -1448.5% | -3620.7% | — | -312631.8% |
| Net margin | -2003.6% | -1358.1% | -2774.6% | — | -279263.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $16,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$13.4M | -$15.2M | -$16.2M | -$16.4M | -$16.8M | -$16.9M | -$18.6M | -$4.6M |
| Net income | -$11.2M | -$28.9M | -$610,000.00 | -$14.1M | -$14.7M | -$18.1M | -$14.5M | -$4.2M |
| Diluted EPS | -$2.45 | -$6.31 | -$0.62 | -$1.41 | -$0.56 | -$0.69 | -$0.07 | -$0.14 |
| Operating cash flow | -$8.3M | -$7.9M | -$13.5M | -$14.1M | -$13.1M | -$9.4M | -$6.9M | -$7.5M |
| Free cash flow | -$8.3M | -$7.9M | -$13.5M | -$14.1M | -$13.3M | -$9.4M | -$6.9M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -28850.0% |
| Net margin | — | — | — | — | — | — | — | -26381.3% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-09 | Rajangam Kanya· Pres. & Chief Med. & Dev. Off. | Tax withholding | 10,757 | $0.00 | $0.00 | filing |
| 2026-03-09 | Lu Timothy K· CEO | Tax withholding | 80,666 | $0.00 | $0.00 | filing |
| 2026-02-02 | Rajangam Kanya· Pres. & Chief Med. & Dev. Off. | Tax withholding | 1,384 | $0.00 | $0.00 | filing |
| 2026-02-02 | Lu Timothy K· CEO | Tax withholding | 4,191 | $0.00 | $0.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.